Plasma biomarker signatures in patients with rapidly progressive dementia
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)
DOI: 10.1002/dad2.70541 ↗At a glance
Journal article in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published online on 2026-11-13. Written by Lindsey A Kuchenbecker and 11 co-authors. Institution: Department of Neuroscience Mayo Clinic in Florida Jacksonville Florida USA. 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIA NIH HHS, National Institute on Aging.
Topics: Demenz
Abstract (original language)
INTRODUCTION Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions. METHODS Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging. RESULTS Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p‐tau)217 and p‐tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment–non‐responsive causes of RPD. DISCUSSION Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts.
Subjects
Author keywords
Authors and institutions
- Department of Neuroscience Mayo Clinic in Florida Jacksonville Florida USA.
- Department of Neurology Mayo Clinic in Florida Jacksonville Florida USA.
- University of Tennessee Health Science Center Knoxville Tennessee USA.
- Institute for Translational Research University of North Texas Health Science Center Fort Worth Texas USA.
- Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA.
ORCID profiles: Lindsey A Kuchenbecker, Gregory S Day
Funding
- NIA NIH HHS
- National Institute on Aging
Cite
APA
Kuchenbecker, L. A., Piura, Y. D., Tipton, P. W., Martens, Y. A., Satyadev, N., Petersen, M., Prudencio, M., Algeciras-Schimnich, A., Figdore, D. J., Graff-Radford, N. R., O'Bryant, S. E., & Day, G. S. (2026). Plasma biomarker signatures in patients with rapidly progressive dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(4). https://doi.org/10.1002/dad2.70541
Vancouver
Kuchenbecker LA, Piura YD, Tipton PW, Martens YA, Satyadev N, Petersen M, et al. Plasma biomarker signatures in patients with rapidly progressive dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(4). doi:10.1002/dad2.70541
BibTeX
@article{Kuchenbecker2026,
author = {Kuchenbecker, Lindsey A and Piura, Yoav D and Tipton, Philip W and Martens, Yuka A and Satyadev, Nihal and Petersen, Melissa and Prudencio, Mercedes and Algeciras-Schimnich, Alicia and Figdore, Daniel J and Graff-Radford, Neill R and O'Bryant, Sid E and Day, Gregory S},
title = {Plasma biomarker signatures in patients with rapidly progressive dementia},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {4},
doi = {10.1002/dad2.70541}
}
EUVIMED